Former Head of Roche Diagnostics, North America, Has 25 Years of Life Sciences Industry Experience

RANCHO CORDOVA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products that process and store adult stem cells, said today that Tiffany P. Olson, formerly President and Chief Executive Officer, Roche Diagnostics Corporation, North America, has been named to the Company's Board of Directors. Her appointment brings the Company's number of directors to six.

Olson, who has more than 25 years of healthcare industry experience, led the over one billion dollar operation for Roche Diagnostics Corporation for three years. Roche Diagnostics is a world-leader in in-vitro diagnostics and specializes in products and services for the molecular, chemistry, immunology, point-of care and life sciences markets. She joined Roche in 1997 and her positions also included Global Market Development and Quality, Vice President, Molecular Diagnostics, United States and other senior positions.

'Tiffany's appointment is emblematic of our initiative to elevate both the Board of Directors and management team at ThermoGenesis. Her extensive experience in key areas of the healthcare industry will provide us invaluable insight as we pursue our growth strategies in that market,' said Dr. William Osgood, Chief Executive Officer of ThermoGenesis.

'This is an exciting time to be associated with ThermoGenesis. It is building upon its already strong position in regenerative medicine through developments such as the recent FDA authorization of its MarrowXpress(TM) and I look forward to working with the management team,' Olson commented.

Olson holds a B.S. in Business from the University of Minnesota School of Management and an MBA from the University of St. Thomas in St. Paul, Minnesota.